Study: NCT05282277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo Patch
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo Patch
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo Patch
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo Patch
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.